Physician profile
Rose Ramirez
NPI 1972565398
$15,066.94
in general payments reported to CMS, 2019-2025
35 companies · $4,961 in 2025
The $4,961 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $2,159 · 2023: $3,158 · 2024: $4,143 · 2025: $4,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $887 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,275.62 |
| Travel and Lodging | $886.53 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,114.80 | 2021-2025 | |
| Enterra Medical, INC. | $1,433.61 | 2024-2025 | |
| Gilead Sciences, INC. | $1,094.98 | 2022-2025 | Epclusa, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $976.86 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $971.50 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $776.64 | 2022-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $639.63 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $552.06 | 2022-2025 | |
| Pfizer INC. | $542.45 | 2022-2025 | |
| Madrigal Pharmaceuticals | $456.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $302.45 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $299.86 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $234.06 | 2022-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $223.04 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $219.20 | 2024-2025 | Zenpep |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $118.80 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $102.66 | 2023-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.77 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $88.27 | 2022-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $84.18 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $79.41 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $77.05 | 2023-2024 | Dificid |
| Celltrion USA INC. | $67.90 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Dova Pharmaceuticals | $65.53 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $61.60 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $60.77 | 2022-2023 | Andexxa |
| Ferring Pharmaceuticals INC. | $57.59 | 2022-2023 | Rebyota |
| Fresenius Kabi USA, LLC | $54.86 | 2023-2024 | Idacio |
| Celgene Corporation | $51.25 | 2023-2024 | Zeposia |
| Sandoz INC. | $46.43 | 2024-2025 | Hyrimoz |
| Braintree Laboratories, INC. | $39.17 | 2022 | |
| Astellas Pharma US INC | $23.06 | 2023 | |
| Alnylam Pharmaceuticals INC. | $21.27 | 2023 | Givlaari |
| Biocon Biologics INC | $20.33 | 2025 | Yesintek |
| Amgen INC. | $17.10 | 2023 | Amjevita, Avsola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.